The recently concluded session had traders exchanging Five Prime Therapeutics, Inc. (NASDAQ:FPRX) high level. Roughly 1.46 million shares changed hands compared to the three-month volume average 0.46 million shares. The first trade took place at $30.1 and the stock went down -8.77% to attain the closing price of $27.77.Five Prime Therapeutics, Inc. (FPRX) Analyst Opinion
Five Prime Therapeutics, Inc. has a consensus buy rating from 9 Wall Street analysts, and the number of shares currently sold short amount to at least 6.87% of shares outstanding. The stock sank -32.22% last month and is down -44.58 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover FPRX having a buy-equivalent rating. Analysts have placed a $61.44 price target on Five Prime Therapeutics, Inc., suggesting a 121.25% gain from recent close. It’s currently trading about -54.46% below its 52-week high.
Five Prime Therapeutics, Inc. (FPRX) failed to surprise the stock market in its last reported earnings when it earned -$1.54 a piece versus the consensus-estimated -$1.24. Its revenue totaled $16.16 million up 106.65% from the previous quarter.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Intraday View
This stock (FPRX) is ahead of its 52-week low with 29.71%. Its last month’s stock price volatility remained 25.59% which for the week stands at 9.6%. The share price has moved backward from its 20 days moving average, trading at a distance of -35.9% and stays -28.99% away from its 50 days moving average. Over the last five days, shares have faced -36.19% losses and now is down -21.64% since hitting its 200-day moving average of $33.2. Five Prime Therapeutics, Inc. (FPRX) has made its way to a 12-month decline of -48.95%.
Turning to Genesis Healthcare, Inc. (NYSE:GEN), its shares were trading at $0.95 a gain of $0.08, on the trading floor. The stock, after opening at $0.84, touched a high of $1 before paring much of its gains. So far, analysts are sticking with their bearish recommendations with the consensus call at 3. Genesis Healthcare, Inc. has 0 buy ratings, 3 holds and 0 sells even after the stock tumbled -80% from its high of $4.75 to a $150.26 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 3 to 3 during a month. Analysts set a 12-month price target of $3.3 a share. The target implies a 247.37% spike from where the shares are currently trading. Also, the current price highlights a discount of 636.84% to analysts’ high consensus price target.Genesis Healthcare, Inc. (NYSE:GEN) Intraday Trading
The counter witnessed a trading volume of 0.91 million shares versus an average volume of 0.61 million shares during last trading session. Its last month’s stock price volatility remained 10.12% which for the week approaches 6.61%. The lowest price the stock reached in the last trading day was $0.84 and compares with the $0.87 52-week low. The stock recovered 9.73% since its low point and has performed -77.65% year-to-date.